Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$539.18 USD
+0.60 (0.11%)
Updated May 10, 2024 04:00 PM ET
After-Market: $539.26 +0.08 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Elevance Health (ELV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$599.76 | $630.00 | $529.00 | 11.36% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Elevance Health comes to $599.76. The forecasts range from a low of $529.00 to a high of $630.00. The average price target represents an increase of 11.36% from the last closing price of $538.58.
Analyst Price Targets (17)
Broker Rating
Elevance Health currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 16 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 88.89% and 5.56% of all recommendations. A month ago, Strong Buy made up 88.89%, while Buy represented 5.56%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 14 | 12 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.19 | 1.21 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/19/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
4/18/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/4/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
3/27/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/1/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
1/24/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 18 |
Average Target Price | $599.76 |
LT Growth Rate | 12.20% |
Industry | Medical Services |
Industry Rank by ABR | 95 of 252 |
Current Quarter EPS Est: | 10.03 |